Encuesta de opinión a pacientes con psoriasis moderada-grave sobre la persistencia de los tratamientos biológicos

[1]  J. Erickson,et al.  Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. , 2016, The New England journal of medicine.

[2]  L. Puig,et al.  Consensus document on the evaluation and treatment of moderate‐to‐severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  M. Lebwohl,et al.  Long‐term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate‐to‐severe psoriasis: results from the PHOENIX 2 study through 5 years of follow‐up , 2015, The British journal of dermatology.

[4]  L. Skov,et al.  Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris , 2015, The British journal of dermatology.

[5]  L. Puig,et al.  Efficacy of biologics in the treatment of moderate‐to‐severe plaque psoriasis: a systematic review and meta‐analysis of randomized controlled trials with different time points , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[7]  J. Koo,et al.  Biologic fatigue in psoriasis , 2014, The Journal of dermatological treatment.

[8]  C. Griffiths,et al.  Definition of treatment goals for moderate to severe psoriasis: a European consensus , 2010, Archives of Dermatological Research.

[9]  F. Nestle,et al.  Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.

[10]  A. Nakanishi,et al.  A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction , 2005, The British journal of dermatology.